Form 4: Sangamo Therapeutics Officer's RSU Tax Withholding

Sangamo Therapeutics' Principal Accounting Officer, Nikunj Jain, reported a disposition of shares for mandatory tax withholding related to restricted stock unit vesting.

Summary

• Nikunj Jain, Principal Accounting Officer of Sangamo Therapeutics, Inc. (SGMO), reported a transaction on January 22, 2026.
• 7,721 shares of Common Stock were disposed of at a price of $0.3985 per share.
• This disposition was solely for mandatory tax withholding purposes related to the vesting of restricted stock units (RSUs) and was not a discretionary trade.
• Following this transaction, Nikunj Jain beneficially owns 242,996 shares of Common Stock.
• The beneficial ownership includes shares from various RSU grants vesting through February 2026 and 5,000 shares acquired under the 2020 Employee Stock Purchase Plan on November 28, 2025.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction related to executive compensation (RSU vesting and tax withholding), which is neutral in sentiment. The officer also acquired shares via an ESPP, which is a minor positive.

Positives

• The vesting of restricted stock units indicates continued employee retention and compensation, aligning management's interests with shareholders.
• The acquisition of 5,000 shares under the Employee Stock Purchase Plan demonstrates ongoing investment by the officer in the company's equity.

Negatives

• The disposition of 7,721 shares, while for tax purposes, reduces the officer's direct shareholding.

Industry Context

This filing is a routine insider transaction report, common across all industries for publicly traded companies when executives' restricted stock units vest and shares are withheld for tax obligations. It does not provide specific industry-related insights.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes related to executive compensation.
• Employees: Reflects standard executive compensation practices, which can be a positive for employee morale and retention.

Next Steps

• Continued vesting of the February 24, 2023 RSU grant in successive equal quarterly installments through February 24, 2026.
• Continued vesting of the February 25, 2025 RSU grant, with the remainder of shares vesting in 8 successive equal quarterly installments after February 25, 2026.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Nikunj Jain, Form 4, SEC filing, restricted stock units, RSU vesting, tax withholding, beneficial ownership, insider transaction, equity incentive plan, employee stock purchase plan